FINWIRES · TerminalLIVE
FINWIRES

Hutchmed's Savolitinib Combo Improves Survival in Lung Cancer Trial; Shares Jump 5%

By

HUTCHMED (China) (HKG:0013) said its savolitinib combination with AstraZeneca's osimertinib significantly improved progression-free and overall survival in a Phase III lung cancer trial.

The SAFFRON trial evaluated patients whose cancer had progressed after osimertinib treatment and whose tumors had high levels of MET, according to a Monday Hong Kong exchange filing. The safety profile was consistent with the known effects of the two drugs, with no new safety findings.

Shares of the company jumped nearly 5% in recent trade.

Related Articles

Asia

Dreadnought Resources Says Rock Chip Sampling Confirms High-Grade Tungsten at Western Australia Projects

Dreadnought Resources (ASX:DRE) said rock chip sampling at both the Mangaroon and Mangaroon South projects in Western Australia confirmed high-grade tungsten, according to a Monday Australian bourse filing.At Mangaroon, rock chip sampling at the Nina target resulted in samples of 6.5% tungsten trioxide and 3.3% tungsten trioxide. The Mulka Well prospect at Mangaroon South confirmed scheelite mineralisation with significant rock chip results including 1.9% tungsten trioxide and 1.4% tungsten trioxide.Drilling at Nina is planned for the end of 2026 or the start of 2027. Systematic sampling and mapping of the Mangaroon South prospects will begin in September.

ASX:DRE
Asia

Fubon Financial Commits Up To $200 Million Investment in StepStone VC Secondaries Fund VII; Shares Down 4%

Fubon Financial Holding (TPE:2881), through its subsidiary Fubon Life Insurance, has committed up to $200 million to Brookfield Infrastructure Fund VI-A, according to a Friday filing to the Taiwan stock exchange.The transaction is with Brookfield Asset Management Private Institutional Capital Adviser (Canada), which is not a related party.The company's shares were down over 4% in Monday's trade.The transaction, approved by the board of directors, represents an estimated 0.67% holding in the fund, the filing showed.

TPE:2881
Asia

Metrocon Holdings Posts MYR2.6 Million Loss for H1

Metrocon Holdings (SGX:WYO), formerly known as Hatten Land, posted an attributable loss of 2.58 million ringgit, or 0.0014 ringgit per share, for the six months ended June 30, according to a Friday filing with the Singapore Exchange.For the 12 months ended June 30, the company reported an attributable loss of 45.5 million ringgit, or 0.0245 ringgit per share.The results relate to Hatten Land, following its reverse takeover of Metrocon, after which Hatten Land changed its name to Metrocon Holdings and its financial year-end to Dec. 31 from June 30.The group's financial statements do not include Metrocon Pte. Ltd., as the acquisition was completed on July 31, after the reporting date.

SGX:WYO